Société de Therapeutique Marocaine Crecimiento futuro

Société de Therapeutique Marocaine's EPS is expected to grow by 7.5% per annum.

n/a

Tasa de crecimiento de los beneficios

7.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	19.4%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

No hay actualizaciones

Previsiones de crecimiento de beneficios e ingresos

CBSE:SOT - Estimaciones futuras de los analistas y datos financieros pasados (MAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	2,630	281	25	143	N/A
3/31/2024	2,558	272	4	122	N/A
12/31/2023	2,486	263	-18	100	N/A
9/30/2023	2,411	262	21	121	N/A
6/30/2023	2,336	260	60	143	N/A
3/31/2023	2,319	264	73	150	N/A
12/31/2022	2,302	267	86	156	N/A
9/30/2022	2,268	286	129	197	N/A
6/30/2022	2,233	306	173	237	N/A
3/31/2022	2,145	293	219	282	N/A
12/31/2021	2,056	279	265	328	N/A
9/30/2021	1,998	264	199	258	N/A
6/30/2021	1,940	249	133	189	N/A
3/31/2021	1,869	240	84	141	N/A
12/31/2020	1,798	230	35	94	N/A
9/30/2020	1,737	233	N/A	N/A	N/A
6/30/2020	1,675	235	N/A	N/A	N/A
3/31/2020	1,680	227	N/A	N/A	N/A
12/31/2019	1,686	220	155	227	N/A
9/30/2019	1,647	173	N/A	N/A	N/A
6/30/2019	1,667	196	N/A	N/A	N/A
3/31/2019	1,629	207	N/A	N/A	N/A
12/31/2018	1,561	182	111	163	N/A
9/30/2018	1,544	208	N/A	N/A	N/A
6/30/2018	1,497	198	N/A	N/A	N/A
3/31/2018	1,456	174	N/A	N/A	N/A
12/31/2017	1,415	150	N/A	193	N/A
9/30/2017	1,400	153	N/A	N/A	N/A
6/30/2017	1,386	155	N/A	N/A	N/A
3/31/2017	1,356	152	N/A	N/A	N/A
12/31/2016	1,326	149	N/A	190	N/A
9/30/2016	1,261	135	N/A	N/A	N/A
6/30/2016	1,195	121	N/A	N/A	N/A
3/31/2016	1,175	119	N/A	N/A	N/A
12/31/2015	1,156	118	N/A	161	N/A
9/30/2015	1,155	115	N/A	N/A	N/A
6/30/2015	1,155	113	N/A	N/A	N/A
3/31/2015	1,138	102	N/A	N/A	N/A
12/31/2014	1,122	92	N/A	137	N/A
9/30/2014	1,125	95	N/A	N/A	N/A
6/30/2014	1,129	97	N/A	N/A	N/A
3/31/2014	1,124	107	N/A	N/A	N/A
12/31/2013	1,119	117	N/A	159	N/A

Ingresos vs. Tasa de ahorro: Insufficient data to determine if SOT's forecast earnings growth is above the savings rate (14.5%).

Beneficios vs. Mercado: Insufficient data to determine if SOT's earnings are forecast to grow faster than the MA market

Beneficios de alto crecimiento: Insufficient data to determine if SOT's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if SOT's revenue is forecast to grow faster than the MA market.

Ingresos de alto crecimiento: Insufficient data to determine if SOT's revenue is forecast to grow faster than 20% per year.

ROE futura: Insufficient data to determine if SOT's Return on Equity is forecast to be high in 3 years time